FendX Announces Granting of United States Patent to Protect REPELWRAP(TM) Film

US Patent Represents FendX’s 5th Patent Issued

Oakville, Ontario–(Newsfile Corp. – November 14, 2024) – FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX“) a nanotechnology company developing surface protection coatings, is pleased to announce that its United States (“US”) patent application was registered as a granted patent on October 8, 2024, further supporting the Company’s commitment to build on its intellectual property position and coverage for the Company’s nanotechnology, its methods and products in development.

Dr. Carolyn Myers, CEO of FendX states, “The US patent represents a significant milestone for us that excludes others from making, using, or selling the innovation that protects our REPELWRAP™ film in the US. We are pleased to receive the final documentation which confirms the issuance, particularly given we recently completed pilot manufacturing runs with Dunmore for REPELWRAP™ film and are preparing for real-world beta testing.”

The US patent number 12,109,586, registered as a patent on October 8, 2024, is titled “Omniphobic Surfaces with Hierarchical Structures, and Methods of Making and Uses Thereof”, which was licensed exclusively by FendX from McMaster University, relates to the making of a repellent surface that has been shown in the lab to reduce contamination on surfaces by significantly reducing bacteria and virus adhesion and transmission.

About FendX Technologies Inc.

FendX is a Canada-based nanotechnology company focused on developing products to make people’s lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has exclusive worldwide licenses to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.

About Dunmore International Corp.

Dunmore International Corp. (“Dunmore“), a Steel Partners Holdings L.P. (NYSE: SPLP) operating company. And is a global manufacturer of engineered coated and laminated films and foils with manufacturing facilities in the U.S. and Germany. Dunmore offers film conversion services such as coating, metallizing, and laminating along with contract film manufacturing and custom film product development. Dunmore services a diverse group of industries including aircraft, spacecraft, photovoltaic, graphic arts & labels, packaging, and insulation. Dunmore is a subsidiary of Steel Partners and is ISO 9001:2015 and OSHA VPP Star certified.

ON BEHALF OF THE COMPANY

“Carolyn Myers”
Carolyn Myers
Chief Executive Officer and Director

For more information, please visit https://fendxtech.com/ and the Company’s profile on SEDAR+ at www.sedarplus.ca.

Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements
This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; statements regarding further building the Company’s intellectual property portfolio and coverage for the Company’s nanotechnology, its methods and products in development; statements regarding patent protection; statements regarding preparing for real-world beta testing; and statements regarding research and development activities, products under development, and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “aims,” “potential,” “goal,” “objective,” “prospective,” and similar expressions, or that events or conditions “will,” “would,” “may,” “can,” “could” or “should” occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and involve several risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and that actual results and future events could differ materially from those anticipated in such statements.

Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history; research and development activities; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other risk factors set forth in the Company’s public filings which are available on SEDAR+ at www.sedarplus.ca. Accordingly, the reader is urged to refer to the Company’s such filings for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors should change.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/229842